Skip to content

US · PPBT · BIOTECHNOLOGY

Purple Biotech Ltd. (PPBT) intrinsic value and stock valuation

$1.53as of 2026-11-21 · Mkt cap 207.13K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Purple Biotech Ltd. DCF and intrinsic value

InvestorsCraft values PPBT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PPBT’s statements →

Purple Biotech Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Rehovot, TA 7670104 purple-biotech.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$0.00
20132025
Net income
-$-26.39M
20132025
Free cash flow
-$-5.54M
20132025
Total equity
$9.66M-34.4% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$0.00$0.00$200K$0.00$0.00
Operating income-$-27.46M-$-11.01M-$-22.27M-$-22.6M-$-17.93M
Net income-$-26.39M-$-7.24M-$-20K-$-21.67M-$-18.38M
EPSd—-$-45.25M-$-181.82K-$-240.78M-$-204.22M
Operating cash flow-$-5.54M-$-14.37M-$-19.93M-$-16.73M-$-15.07M
Capital expenditure-$0.00$0.00-$0.00-$-230K-$-120K
Free cash flow-$-5.54M-$-14.37M-$-19.93M-$-16.96M-$-15.19M
Total assets$17.6M$37M$44.3M$54.6M$70.2M
Total debt$240K$180K$350K$520K$750K
Net debt-$-8.47M-$-7.22M-$-14.14M-$-14.52M-$-10.14M
Total equity$9.66M$32.9M$34.3M$47.1M$65.1M
Cash and short-term investments$9.57M$8.52M$15.4M$32.1M$47.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$200K$0.00$0.00
Cost of revenue$0.00$190K$200K$0.00$0.00
Gross profit$0.00-$-190K-$0.00-$0.00-$0.00
Research and development expenses$3.73M$7.62M$17M$16.3M$11.8M
Selling, general and administrative expenses$2.98M$2.94M$4.84M$5.96M$5.82M
Other expenses$20.7M$450K$390K$320K$10K
Operating expenses$27.5M$11M-$-22.47M$22.6M$17.9M
Cost and expenses$27.5M$11M$22.3M$22.6M$17.9M
Interest income$230K$260K$470K$530K$320K
Interest expense$40K$450K$2.18M$70K$210K
Depreciation and amortization$200K$190K$50K$200K$230K
Ebitda-$-26.25M-$-7.05M-$-19.88M-$-21.49M-$-17.52M
Operating income-$-27.46M-$-11.01M-$-22.27M-$-22.6M-$-17.93M
Total other income/expenses, net$970K$3.73M$2.29M$840K$110K
Income before tax-$-26.49M-$-7.28M-$-19.98M-$-21.76M-$-17.83M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-26.39M-$-7.24M-$-20K-$-21.67M-$-18.38M
Weighted average shares outstanding$0.00$160K$110K$90K$90K
Weighted average diluted shares outstanding$0.00$160K$110K$90K$90K
Balance sheet
20252024202320222021
Cash and short-term investments$9.57M$8.52M$15.4M$32.1M$47.2M
Net receivables$150K$280K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$9.87M$8.91M$15.8M$33.3M$48.5M
Property, plant and equipment, net$350K$290K$470K$680K$900K
Goodwill and intangible assets$7.36M$27.8M$28M$20.7M$20.5M
Long-term investments$0.00$0.00$0.00$0.00$190K
Total non-current assets$7.71M$28.1M$28.5M$21.4M$21.7M
Total assets$17.6M$37M$44.3M$54.6M$70.2M
Accounts payable$2.07M$1.46M$3.53M$2.13M$1.47M
Short-term debt$240K$370K$190K$190K$200K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.75M$3.99M$7.18M$7.06M$4.25M
Long-term debt$0.00$0.00$160K$320K$550K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$160K$140K$2.82M$470K$840K
Capital lease obligations$240K$180K$350K$520K$750K
Total liabilities$7.91M$4.13M$10M$7.52M$5.09M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-171.08M-$-144.69M-$-137.45M-$-117.58M-$-95.91M
Accumulated other comprehensive income (loss)$28.3M-$-100K-$-80K$38.1M$36.8M
Total equity$9.66M$32.9M$34.3M$47.1M$65.1M
Total investments$860K$1.12M$920K$17.1M$36.5M
Total debt$240K$180K$350K$520K$750K
Net debt-$-8.47M-$-7.22M-$-14.14M-$-14.52M-$-10.14M
Cash flow statement
20252024202320222021
Net income-$-26.39M-$-7.28M-$-19.88M-$-21.76M-$-17.83M
Depreciation and amortization$200K$190K$200K$200K$230K
Stock-based compensation$310K$580K$1.88M$2.41M$2.08M
Change in working capital$810K-$-4.33M$270K$3.25M$550K
Accounts receivable$150K$0.00$0.00$310K-$-320K
Inventory$0.00$0.00$0.00$2.13M$570K
Accounts payable$450K-$-2.08M$1.33M$800K$270K
Net cash provided by operating activities-$-5.54M-$-14.37M-$-19.93M-$-16.73M-$-15.07M
Investments in property, plant and equipment-$0.00$0.00-$0.00-$-230K-$-120K
Acquisitions, net$0.00$0.00-$-3.55M$0.00$0.00
Net cash used for investing activities$450K$510K$13.9M$19.9M$13.4M
Common stock issued$6.63M$5.81M$1.56M$1.5M$560K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.41M$6.77M$5.45M$1.11M$1.51M
Net change in cash$1.32M-$-7.09M-$-540K$4.14M-$-360K
Cash at end of period$8.72M$7.4M$14.5M$15M$10.9M
Operating cash flow-$-5.54M-$-14.37M-$-19.93M-$-16.73M-$-15.07M
Capital expenditure-$0.00$0.00-$0.00-$-230K-$-120K
Free cash flow-$-5.54M-$-14.37M-$-19.93M-$-16.96M-$-15.19M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Purple Biotech Ltd.

        Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.

        CEO
        Gil Efron
        Employees
        10
        Beta
        -0.55

        Explore

        Frequently asked questions

        What is the intrinsic value of Purple Biotech Ltd. (PPBT)?

        InvestorsCraft does not currently publish an intrinsic value for PPBT. How the IC value is calculated.

        Is PPBT undervalued?

        InvestorsCraft does not publish an undervaluation signal for PPBT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.